Mymetics announces change of directors and management

Will explore a number of strategic opportunities for its HIV, RSV and other vaccine candidates

Mymetics Corporation, a Swiss developer of vaccines that use the human mucosal system to prevent transmission of infectious diseases, has promoted Ronald Kempers, formerly the company’s CFO and COO, to president and CEO. He has replaced Christopher Henney and Grant Pickering, who were director and chairman and president and CEO respectively and will pursue new strategic directions, including the potential change of Mymetics’ location from Switzerland to the US.

Mymetics will maintain its principal place of business in Switzerland as it explores a number of strategic opportunities for its HIV, RSV and other vaccine candidates under development.

The company will provide an update in due course.

You may also like

Research & Development

Mymetics-led consortium awarded €8.4m to develop thermo stable and cold-chain independent vaccines

Virosome vaccine technology and HIV vaccine candidate to be used to develop scalable manufacturing process within 3.5 years
Research & Development

Mymetics to advance development of virosome-based malaria vaccine candidate

In partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the NIH
Research & Development

Mymetics’ HIV vaccine candidate to begin study at Texas Biomedical Research Institute

Follows a successfully completed smaller study at the Institute of Laboratory Animal Science (ILAS)
Research & Development

Astellas forms partnership with ClearPath to build vaccine portfolio

In-license vaccine technology for Respiratory Syncytial Virus (RSV) from Mymetics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now